ARTICLE | Finance
With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein
For Tony Coles’ neuroscience company, the deal effectively replaces a more traditional path to going public
July 30, 2020 11:08 AM UTC
Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies.
Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check shell companies that are set up to merge with private companies after themselves going public...